We regularly ask our product experts and industry leaders to talk about topics that matter to our customers. Helping you to overcome real-world research problems, answering your technical questions, or highlighting our latest product innovations, our webinar series has something for everyone.
If you missed a webinar, then we’re pleased to offer you FREE access to our library of informative, engaging and interactive presentations. Simply click on the relevant link to watch the webinar.
If you’d like to see what we’ve got coming up, please visit our events page which is updated regularly with new webinars, global events, seminars and trade shows.
Custom Antibody Development Approaches for Generating Anti-Idiotype Monoclonal Antibodies for PK Assays
Join Dr. Stephen Pelsue, Science Director at BBI Solutions, in our webinar focused on the development of anti-idiotype (anti-id) antibodies. Anti-id monoclonal antibodies are critical for bioanalytical pharmacokinetic (PK) assays that are required to ensure the safety and efficacy of therapeutic antibody drugs.
The convergence of point of care testing (POCT) and the mobile phone has the potential to revolutionise diagnostics. Yet, misconceptions exist about the capability of a smartphone to accurately read and share the results of diagnostic tests.Download our webinar recording as we myth bust the common misconceptions surrounding smartphone readers and demonstrate how the technology is already transforming point of care testing.
Join Dr. Neil Polwart, Founder of Novarum and BBI Group Head of Mobile in our webinar, where he will discuss how the healthcare sector is on the verge of a mhealth revolution and demonstrate how a lateral flow test can support home testing and self-patient care using nothing more than a smartphone.
This webinar will explore the basic principles of lateral flow, component parts to insights into the benefits and limitations of the technology. Our informative interactive session will also cover topics such as material selection and development considerations as well as common pitfalls to avoid when developing an assay. If you’re struggling to reach the limit of detection or achieve sensitivity for your tests, this is your opportunity to ask the experts.
In this webinar Dr. Catharine Sturgeon from UK NEQAS sets out the case for an international effort to standardise manufacturer’s assays for mucin tumour markers, such as CA125, CA15-3 and CA19-9. If the benefits of standardisation clearly improve between-laboratory comparability of immunoassay results, then this could be a key consideration for endorsement by governing bodies in the future. Stay ahead of the game and learn how you can future proof your tumour marker assay.